Search Results
Your search for ,USE matches 11256 pages
Showing 6851 - 6900Examining the Impact of ‘Death With Dignity’ Legislation
Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
Implications of SWOG S0777 and the Future of Combination Treatments for Multiple Myeloma
The treatment of multiple myeloma is becoming increasingly complicated. This is not only because of the complexity of the disease, but also because of the increasing number of effective combination treatments and continuous development of new drugs. This has resulted in an ever-increasing number ...
New First-Line Options for ALK-Positive Lung Cancer on the Horizon
Anaplastic lymphoma kinase (ALK) rearrangements define a subset of non–small cell lung cancer (NSCLC) patients for whom ALK inhibitors are highly effective. In PROFILE 1014, the multitargeted ALK inhibitor crizotinib (Xalkori) was shown to be superior to platinum/pemetrexed (Alimta) chemotherapy...
Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC
In the phase III ASCEND-4 trial reported in The Lancet, Jean-Charles Soria, MD, of Institut Gustave Roussy, and colleagues found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in the first-line treatment of advanced anaplastic lymphoma kinase...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
The Art of Medicine in the World of Evidence-Based Medicine
Christian Taverna, MD, a lymphoma specialist at the Hospital Münsterlingen in Switzerland, commented on this patient series for The ASCO Post. He noted that the Swiss Group for Clinical Cancer Research (SAKK) tried to address the question of the optimal duration of rituximab (Rituxan) maintenance...
For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
Expert Point of View: Heather L. McArthur, MD, MPH
Discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, Los Angeles, called the plinabulin findings “provocative,” especially considering the substantial impact on durability of response. Specifically with the addition of plinabulin to docetaxel, ...
Breast Surgeon Sheldon M. Feldman, MD, Joins Montefiore and Einstein Cancer Centers
Sheldon M. Feldman, MD, has been named Chief of the Division of Breast Surgery and Surgical Oncology and Director of Breast Cancer Services at Montefiore Einstein Center for Cancer Care, the clinical arm of the National Cancer Institute–designated Albert Einstein Cancer Center. He will also join...
IASLC Endorses Tobacco Reform Report Outlining Progress Toward Ending Adult Cigarette Smoking
The International Association for the Study of Lung Cancer (IASLC) has endorsed a report released by the Core Team for Tobacco Control that outlines key action items that can be taken immediately to accelerate progress toward ending cigarette smoking in adults. Issuing their Executive Summary ...
Search Continues for Effective Way to Prevent Lymphedema in Breast Cancer Survivors
There was no difference in the incidence of lymphedema at 18 months in breast cancer patients randomized to a physical therapy intervention with education materials compared with a control.1 Although poor adherence to the intervention may have been a factor, these results, described as “very...
Expert Point of View: Manish A. Shah, MD
Manish A. Shah, MD, Director of Gastrointestinal Oncology at NewYorkPresbyterian and Weill Cornell Medicine, commented that “the benefit seen in patients who regularly exercise is equal to or better than the benefit seen with some chemotherapy drugs,” although he cautioned that exercise in this...
Expert Point of View: Nancy Baxter, MD, PhD & Steven H. Lin, MD, PhD
“CALGB 80803 really helps move the field forward,” said press briefing moderator and ASCO spokesperson Nancy Baxter, MD, PhD, a surgeon from St. Michael’s Hospital in Toronto, Ontario, Canada. “PET [positron-emission tomography] scans may prove to be a valuable tool to help oncologists fine-tune...
Early PET Imaging May Guide Treatment Decisions in Esophageal Cancer
In patients with resectable esophageal or gastroesophageal junction cancer, positron-emission tomography (PET) imaging was used to assess response to induction chemotherapy. PET nonresponders were identified after the first few cycles and were switched to an alternate regimen. This strategy greatly ...
Expert Point of View: Partow Kebriaei, MD
Partow Kebriaei, MD, Professor in the Department of Stem Cell Transplant and Cellular Therapy at The University of Texas MD Anderson Cancer Center, Houston, commented on the findings presented by Marty et al for The ASCO Post. “In this multicenter, randomized, placebo-controlled study, the use of...
Progress Being Made in Understanding Immunotherapy Resistance
A key challenge in advancing immunotherapies is to understand mechanisms of response and resistance. Emerging research in this area—including evidence that early on-treatment biopsies can predict response—was discussed at the 2017 ASCO-SITC (Society for Immunotherapy of Cancer) Clinical...
The Path Forward for Clinical Pathways in Oncology
The year 2016 was a memorable one for oncology. In January, President Barack Obama announced the launch of the National Cancer Moonshot initiative, spearheaded by Vice President Joe Biden, which aims to accelerate cancer research. And in December, through bipartisan Congressional support, the 21st ...
Expert Point of View: Ann W. Silk, MD
Ann W. Silk, MD, of Rutgers Cancer Institute of New Jersey, New Brunswick, presented the day’s highlights and commented that the study by Hellmann et al shows the utility, and, in fact, the necessity, of developing a new means of estimating outcomes for patients treated with immunotherapies....
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
Suboptimal BMD Evaluation in Postmenopausal Women With Early-Stage Breast Cancer Receiving Aromatase Inhibitors
In a study reported in the Journal of Oncology Practice, Stratton et al found that most postmenopausal Medicare patients with early-stage breast cancer receiving aromatase inhibitor therapy do not receive recommended bone mineral density (BMD) measurements. Most expert panels recommend BMD...
Testosterone Replacement Therapy and Risk of Prostate Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Loeb et al found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among men developing the disease. Study Details The ...
Association of Metformin Use for Diabetes With Outcomes in HER2-Positive Breast Cancer
In an analysis from the phase III ALTTO trial reported in the Journal of Clinical Oncology, Sonnenblick et al found that among patients receiving adjuvant therapy for HER2-positive breast cancer, those with diabetes who received metformin had better outcomes than those who did not receive...
ASCO Releases Its State of Cancer Care in America: 2017 Report
In a press briefing today on Capitol Hill, ASCO presented its fourth annual State of Cancer Care in America: 2017 report, which found that although the cancer care delivery system in the United States is undergoing profound changes to better meet the needs of cancer survivors, persistent hurdles...
Dexamethasone Mouthwash in Preventing Everolimus-Related Stomatitis in Women With Breast Cancer
In the phase II SWISH study reported in The Lancet Oncology, Rugo et al found that use of a dexamethasone-based mouthwash may prevent everolimus-related stomatitis in postmenopausal women receiving everolimus (Afinitor) for hormone receptor–positive, HER2-negative metastatic breast cancer....
Jennifer Ho, MD, on Thoracic Cancers: Reirradiation With IMPT
Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity in patients who can have extended survivals; the data also suggest that higher doses may improve...
Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunotherapy, and some of the controversies now debated.
Thoracic 2017: Proton Therapy Offers New Treatment Possibility for Recurrent Lung Cancer
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients ...
Thoracic 2017: Biomarker Test Shows Cancer Recurrence Months Before CT Scans
Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of 6 months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating...
SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases
To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...
FDA Approves Pembrolizumab for Relapsed or Refractory Classical Hodgkin Lymphoma in Adult and Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care
A new study demonstrates that the use of less radiation therapy for patients with breast cancer who have undergone lumpectomy does not negatively impact patient outcomes, and could result in significant reductions in health-care costs. These findings, which examine patient eligibility for...
Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
As reported in the Journal of Clinical Oncology by Dhesy-Thind, ofJuravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer. The...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
Use of Evidence-Based Prostate Cancer Imaging in an Integrated Health-Care System
In a study reported in the Journal of Oncology Practice, Salloum et al found that use of nonindicated imaging for diagnostic staging of low-risk prostate cancer in a nonprofit integrated health-care system remained common but has decreased in frequency. As noted by the authors: “The overuse...
Dutch Study Examines Effect of Internet-Based Cognitive Behavioral Therapy on Sexual Functioning in Breast Cancer Survivors
In a Dutch study reported in the Journal of Clinical Oncology, Hummel et al found that use of an Internet-based cognitive behavioral therapy intervention improved sexual functioning among breast cancer survivors. Study Details In the study, 169 women with a diagnosis of sexual dysfunction from 10 ...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
Ibrutinib in Marginal Zone Lymphoma
On January 19, ibrutinib (Imbruvica) was granted accelerated approved for treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20–based therapy.1 Supporting Efficacy Data Approval was based on overall response rate in a...
Low-Grade Gliomas: Understanding the New Treatment Paradigm
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed, as detailed in a recent review in the Journal of Oncology Practice.1 The...
Royal Swedish Academy of Sciences Inaugural Sjöberg Prize Awarded to James P. Allison, PhD, and Tony Hunter, PhD
The Royal Swedish Academy of Sciences (RSAS) has decided to award the inaugural Sjöberg Prize 2017 to James P. Allison, PhD, Professor and Vivian L. Smith Distinguished Chair in Immunology at The University of Texas MD Anderson Cancer Center, and Tony Hunter, PhD, American Cancer Society...
Value-Based Approaches to the Rising Costs of Cancer Drugs
It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patients. Peter B....
Scientists Tackle Next Set of Immunotherapy Challenges
Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from...
Can Antiviral Therapy Prevent Liver Cancer in Patients With Chronic Hepatitis?
Chronic viral hepatitis is a major causative factor for hepatocellular carcinoma, but antiviral therapy might reduce the incidence of hepatocellular carcinoma by preventing or eliminating chronic hepatitis infections, according to Adrian M. Di Bisceglie, MD, Professor of Internal Medicine at Saint ...
Study Identifies How Cancer Cells May Develop Resistance to FGFR Inhibitors
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC– James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth...
Cisplatin-Based Chemotherapy in Pediatric Extracranial Malignant Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Shaikh et al, of the Children’s Oncology Group, found that event-free survival rates were not maintained with the use of reduced and compressed cisplatin-based regimens in children and adolescents with intermediate-risk extracranial...
Clinical Trials Actively Recruiting Patients With Colorectal Cancer
Phase I Study Title: A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine and Cyclophosphamide in Metastatic Colorectal Cancer as Maintenance Therapy Study Type: Phase I/interventional/parallel assignment Study Sponsor and Collaborators: Sidney Kimmel Comprehensive...
Cervical Cancer Mortality Is Higher and Racial Disparity Wider Than Previously Reported
Cervical cancer mortality rates were significantly higher, particularly among black women, when national data were corrected to exclude women who have had hysterectomies. For black women, the cervical cancer mortality rate rose from 5.7 to 10.1 per 100,000 when corrected for hysterectomy, an...
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10-mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. Clinical Trial Findings The...
